TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 21-45 years old,~* weight 40-90 kg,~* height 145-170 cm~Exclusion Criteria:~* contraindications to spinal anaesthesia,~* allergy to drugs used in the study, and~* those with uncontrolled medical conditions such as hypertension, diabetes mellitus, and cardiovascular disease

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- vasopressor delivery automated system (Type: EXPERIMENTAL): vasopressor delivery automated system administering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
- manual vasopressor delivery (Type: ACTIVE_COMPARATOR): manual bolus delivering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caffeine for Apnea of Prematurity (CAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* birthweight 500 to 1250 grams~* postnatal age day 1 to day 10~* infant considered a candidate for methylxanthine therapy by clinical staff~Exclusion Criteria:~* dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment~* unlikely to comply with long-term follow-up~* prior treatment with a methylxanthine

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Days
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 3 to \< 12 months~* Diagnosis of AD fulfilling the diagnostic criteria of Seymour~* AD affecting at least 5% total body surface area~* Investigator's Global Assessment (IGA) score of 2 or 3, corresponding to mild-to-moderate disease at baseline~* Informed consent~Exclusion Criteria:~* Phototherapy, systemic therapy (e.g., immunosuppressants, cytostatics), systemic corticosteroids within 4 weeks~* Topical tacrolimus or pimecrolimus within 2 weeks~* Topical therapy (e.g., tar, topical corticosteroids) within 3 days~* Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have a history of malignant disease~* Active acute viral skin infection (e.g. herpes simplex, herpes zoster, chicken pox), and/or clinically infected AD~* Failure to thrive (e.g., weight or height/length below the 5th percentile) or developmental abnormalities such as head circumference less than 5th and more than 95th percentile~* Known hypersensitivity to any ingredient of pimecrolimus cream 1% or topical corticosteroids~* Clinical conditions other than AD that according to investigator can interfere with the evaluation

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Pimecrolimus
- 2 (Type: ACTIVE_COMPARATOR): Topical corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROMUS Element Plus US Post-Approval Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The population will include consecutive, consented patients.~Exclusion Criteria:~* There are no exclusion criteria in this all-comers study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PROMUS Element (Type: EXPERIMENTAL): Subjects who receive the PROMUS Element everolimus-eluting coronary stent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:Fifteen non-smokers (males and females between the ages of 18 and 65 years) with physician-diagnosed moderate persistent asthma and FEV1 \< 75% of predicted.~Exclusion Criteria:Cardiovascular disease and use of cardiovascular medications, pregnancy, use of oral controller medication for asthma (methylxanthines, systemic glucocorticosteroids, leukotriene modifiers), an acute respiratory infection within 4 weeks before enrollment~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- mometasone 400 mcg - 30 min (Type: EXPERIMENTAL): randomly assigned intervention
- mometasone 400 mcg simultaneous (Type: EXPERIMENTAL): randomly assigned intervention
- placebo- 30 min (Type: PLACEBO_COMPARATOR): randomly assigned intervention
- placebo simultaneous (Type: PLACEBO_COMPARATOR): randomly assigned intervention
- mometasone 400 mcg - 60 min (Type: EXPERIMENTAL): randomly assigned intervention
- placebo- 60 min (Type: PLACEBO_COMPARATOR): randomly assigned intervention
- mometasone 200 mcg - 30 min (Type: EXPERIMENTAL): randomly assigned intervention
- mometasone 200 mcg - 60 min (Type: EXPERIMENTAL): randomly assigned intervention
- mometasone 200 mcg simultaneous (Type: EXPERIMENTAL): randomly assigned intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Homoeopathy and Physiotherapy in Chronic Low Back Pain Due to Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must present with symptomatic chronic lower back pain due to OA for more than 3 months and having been diagnosed by a health care practitioner with OA;~* They must have symptoms of OA such as pain and decreased range of motion, on subjective and physical examination and~* Participants must be receiving physiotherapy treatment from a specific and identified physiotherapist~Exclusion Criteria:~* Participants who are receiving any other forms of therapy other than physical therapy (massage and thermotherapy), for example osteopathy, acupuncture, ultrasound or electrotherapy as part of physiotherapy treatment;~* Those presenting with acute lower back pain (with duration of only 3 months or less) and those suffering from chronic lower back pain as a result of disc herniation, compression fracture, lumbar spinal stenosis or spondylolisthesis.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Homeopathic complex and physiotherapy (Type: EXPERIMENTAL): Homeopathic complex and physiotherapy: (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of 168 tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist.
- Placebo and physiotherapy (Type: PLACEBO_COMPARATOR): Placebo and Physiotherapy: Placebo will comprise of 168 unmedicated lactose tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Advanced stage idiopathic Parkinson's disease~Exclusion Criteria:~* Well controlled on levodopa

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Major Depressive Disorder or Bipolar Disorder; must be currently depressed~* May be medicated or unmedicated~Exclusion Criteria:~* Contraindication for MRI due to metal in eyes/head~* Claustrophobia.~* Inability to lie flat.~* History of brain injury.~* Pregnant~* Current drug use/abuse/dependence~* History of polysubstance use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sham (inactive) Treatment BPD (Type: SHAM_COMPARATOR): 20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
- Active LFMS treatment in BPD (Type: ACTIVE_COMPARATOR): 20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
- Sham LFMS Comparator: in MD (Type: SHAM_COMPARATOR): 20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
- Experimental LFMS: in MD (Type: ACTIVE_COMPARATOR): 20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed nonmetastatic, unresectable pancreatic adenocarcinoma No evidence of metastatic disease in the major viscera and no peritoneal seeding Residual disease after resection (R-1 or -2 micro- and macroscopic residual) eligible if measurable disease on the post operative CT or MRI scan Recurrent disease following radical surgery is eligible All malignant disease must be encompassable within a single irradiation field Must be a radiographically assessable disease CT with 5 mm cuts or spiral CT~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,800/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL Biliary system stented Renal: Creatinine less than 3.0 mg/dL OR Creatinine clearance at least 40 mL/min Other: If patients have biliary or gastroduodenal obstruction, they must have drainage prior to starting chemoradiation Oral intake of at least 1,500 calories per day No significant infection or other coexistent medical condition~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior paclitaxel At least 4 weeks since prior gemcitabine No other prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the planned field Surgery: See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pacilitaxel + External Beam Radiation Therapy (PXRT) (Type: EXPERIMENTAL): Paclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efficacy and Safety With the Transdermal Contraceptive System.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy women with regular menstrual cycles~* sexually active and at risk of pregnancy~* nonpregnant~* acceptable body mass index (BMI)~* last term pregnancy at least 42 days prior, nonlactating, with 1 normal menstrual cycle since~* sitting BP\<140mmHg/\<90mmHg~* 1 normal menstrual cycle since removal of IUD or norplant~* agreement to use study drug for contraception for up to 13 cycles, except when backup contraception is required for disease protection or patch detachment~* agree not to use other systemic steroid medication~Exclusion Criteria:~* Presence, history, hereditary predisposition or risk of deep vein thrombophlebitis or thromboembolic disorders~* cerebral vascular or coronary artery disease, hypertension, or severe migraines~* liver tumor resulting from estrogen-containing products~* diabetes mellitus~* cholestatic jaundice, liver or renal disease~* abnormal PAP smear~* thyroid disorder~* dermal hypersensitivity~* carcinoma of breast, endometrium or other estrogen-dependent neoplasia~* substance abuse~* received experimental drug within prior 30 days~* smoking women over 35 years of age.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed non-clear cell renal cell carcinoma~* confirmed metastatic sites~* no chemotherapy in history~Exclusion Criteria:~* metastases in CNS~* previous targeted therapy~* other tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Capecitabine (Type: EXPERIMENTAL): All patients will receive capecitabine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Individuals with chronic HCV genotype 1 infection~* Documented as treatment experienced with a direct acting antiviral-containing regimen without achieving sustained viral response~* Absence of cirrhosis or presence of compensated cirrhosis~* Screening laboratory values within defined thresholds~* Must use specific contraceptive methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Co-infection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol~* Pregnant or a nursing female~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL/VOX (Type: EXPERIMENTAL): SOF/VEL/VOX for 12 weeks
- SOF/VEL/VOX + RBV (Type: EXPERIMENTAL): SOF/VEL/VOX + RBV for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and non-pregnant women, at least 20 years of age with chronic genotype 1 HCV and HIV co-infection.~* HCV RNA \> 10,000 IU/mL~* Stable antiretroviral therapy (ARV) with confirmed plasma HIV-1 RNA \< 200 copies/mL~* CD4 T-cell count \> 100 cells/L~* peginterferon alfa plus ribavirin failure: null response \<1 log10 IU/mL reduction in HCV RNA at week 4; detectable HCV RNA since week 12 to the end of treatment; detectable HCV RNA for 12 to 24 weeks after the end of treatment; or discontinuation of peginterferon alfa plus ribavirin due to grade 3 or grade 4 adverse effects at any moment.~Exclusion Criteria:~* Decompensated liver disease (presence or history of ascites, oesophageal or gastric variceal bleeding, hepatic encephalopathy, or other signs of advanced liver diseases)~* Liver cirrhosis with Child-Pugh class B or C, or with a Child-Turcotte-Pugh score of more than 6 points and albumin below 3 g/dL or platelet count below 75,000/ μL~* History of malignant disease, or evidence of hepatocellular carcinoma~* ARV with protease inhibitor containing regimen HBsAg and HBV core antibody should be checked in all patients. HBsAg positive patients should be excluded from the study. HBV core antibody positive patients should be closely monitored for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Appropriate patient management should be instituted for HBV infection as clinically indicated.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Genotype 1 HCV and HIV co-infection (Type: EXPERIMENTAL): Patients with chronic Genotype 1 HCV and HIV co-infection, with or without resistance-associated substitution (RAS) of NS5A, received grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and patients with chronic genotype 1b received grazoprevir and elbasvir once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Restylane-L for Correction of Infraorbital Hollows

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate or severe infraorbital hollows with no more than one grade difference between the left and right side at baseline as assessed by the blinded evaluator.~* Males or non-pregnant, non-breastfeeding females, over the age of 21.~* Intent to undergo correction of both orbital hollows.~Exclusion Criteria:~* Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins.~* Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics.~* Previous deep and/or superficial facial dermal therapies.~* Active or a history of recurrent or chronic infraorbital edema or rosacea or uncontrolled severe seasonal allergies.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Restylane-L Treatment (Type: EXPERIMENTAL): Restylane-L® injected with optional touch-up at 1 month and optional retreatment at 12 months.
- No Treatment Control (Type: NO_INTERVENTION): No treatment control with optional treatment at 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete